Canadian MS Progression Cohort: Administrative Data Analysis
Which patient factors (age, concurrent medications, education, socio-economic status, employment, family support), disease (duration, subtype), treatment (lack of DMT, lack of exposure to high-efficacy DMT, delayed start of DMT), and health systems factors (public/private drug coverage, distance from MS clinic, access to multi-disciplinary resources, access to community support groups) associated with the
de novo onset of disease progression in MS?
Which patient, disease, treatment, and health systems factors (as listed above) are affecting the rate of progression in MS?
What is the health economic impact (i.e. quality of life/health utility, health care resource utilization, productivity loss) of disease progression (de novo onset and rate) and how the magnitude of the burden differs by patient characteristics?
We hypothesize that certain patient characteristics such as age, concurrent medications, disease, and treatment (lack of DMT, lack of exposure to high-efficacy DMT, delayed start of DMT), are associated with the de novo onset and rate of disease progression in MS. Understanding these factors may help predict patient outcomes.